# Vintage Victory: Warfarin Versus Apixaban in the Antiphospholipid Arena

## TL;DR

This case report compares warfarin and apixaban in treating antiphospholipid syndrome, suggesting warfarin may be more effective.

## Contribution

The report highlights warfarin's potential superiority over apixaban in managing antiphospholipid syndrome.

## Key findings

- A patient with APS did not respond to apixaban therapy.
- Transitioning to warfarin resolved symptoms and prevented complications.
- The case supports further evaluation of warfarin over DOACs in APS treatment.

## Abstract

This case report explores the efficacy of warfarin compared to apixaban in managing antiphospholipid syndrome (APS), an autoimmune disorder characterized by recurrent thrombosis. We emphasize the constraints of direct oral anticoagulants (DOACs) such as apixaban in APS management. This case discusses a 41-year-old female patient with APS who did not respond to apixaban therapy. The report details her transition to warfarin, resulting in symptom resolution and no further complications, thus alluding to warfarin's effectiveness in APS management over apixaban. The case contributes to the ongoing debate on the suitability of modern DOACs in APS treatment.